COGNITION THERAPEUTICS Business Summary

Cognition Therapeutics Inc. (CGTX) is a clinical-stage biopharmaceutical company that generates revenue primarily through non-dilutive government grants and strategic equity offerings, as it currently has no commercialized products. The company operates in a single business segment focused on the discovery and development of small molecule therapeutics targeting age-related neurodegenerative disorders, specifically Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD). Its lead candidate, zervimesine (CT1812), is an orally delivered modulator of the sigma-2 receptor (S2R) complex designed to restore synaptic health by preventing the binding of toxic oligomers. Direct competitors include Anavex Life Sciences, Cassava Sciences, and Athira Pharma, with Cognition positioning itself as a specialized player utilizing a unique synaptic-protection mechanism that complements or provides an alternative to the amyloid-beta clearance strategies of larger peers like Biogen and Eli Lilly. The company was founded by a team of industry veterans including Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano, PhD, the latter of whom served as the architect of its core science. Leadership is currently spearheaded by President and CEO Lisa Ricciardi, who brings extensive experience from Suono Bio and Pfizer, and CFO John Doyle, who joined in 2023 with a background in capital markets and commercialization strategy. The executive team also includes Dr. Anthony Caggiano as Chief Medical Officer and Head of R&D, and Dr. Steven Weissman as VP and Head of CMC. Cognition is supported by a robust board of directors chaired by Jack Khattar and featuring Brett Monia, CEO of Ionis Pharmaceuticals. Notable institutional investors include Tocqueville Asset Management, Essex Financial Services, and Vanguard, reflecting sustained interest in the company’s high-stakes clinical pipeline.